Coronis is a leading Israeli Investment Company specializing in the Biotechnology sector and focusing on highly select opportunities in the therapeutic, diagnostic and agro-bio space. Coronis' team, comprised of industry experts with complementary expertise from operational, finance, and management backgrounds, has invested since 2004 over $10M in seven high quality portfolio companies. As of August 2009, Coronis' portfolio valuation has doubled , representing an IRR of more than 30% per year. |
.JPG)
Study of hGH-CTP Given Once-Weekly to Growth Hormone Deficient Adults for Four Months Reaffirms Prior Phase II Findings Showing a Single Weekly Injection of hGH-CTP has Potential to Replace Seven Daily Injections of Commercial hGH.JPG)
MOD-6030 Administered Once Weekly Over 30 Days Produced 28% Weight Loss and Improved Glycemic Profiles.
Other Potential Health Benefits Included 57% Reduction in Cholesterol Levels.
Data to Be Presented at 5th Diabetes Drug Discovery and Development Conference..JPG)
Factor VIIa-CTP May Provide Hemophilia Patients Prolonged Protection from Bleeding Episodes.bmp)
MultiPlan is one of the largest PPOs in the US, with 20 million subscribers and 900,000 health providers who work with 1,400 insurance companies..JPG)
Interferons are proteins produced in response to the presence of tumor cells or pathogens. The estimated worldwide market for interferons is approximately $8 billion..bmp)
Molecular diagnostics company Glycominds is poised to enter the Israeli market - having received approval to register its multiple sclerosis tests with the Israeli Patent Office.
.gif)
Over 200,000 SNPs identified in wheat genome as part of effort to improve wheat traits through advanced breeding
.JPG)
Factor VIIa-CTP May Provide Hemophilia Patients Prolonged Protection
from Bleeding. PROLOR Now Has Two Promising Long-Acting Coagulation Factors with the Potential to Address Important Unmet Medical Needs..JPG)
Trial of hGH-CTP in Growth Hormone Deficient Adults Achieved Key Efficacy and Safety Endpoints..bmp)
The goal of these trials is to examine different parameters for treating multiple sclerosis. At the same time, Glycominds will examine its test's ability to predict the disease's rate of progression.
.JPG)
PROLOR has received a notice of allowance from the U.S. - PTO for a patent application covering the company’s CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins..gif)
BiondVax’s Multimeric-001 Universal Influenza Vaccine successfully meets primary and secondary endpoints with strong safety and immunogenicity data in 200 participants
